| abstract |
Use of tetrahydroisoquinoline derivatives of general formula wherein A is aryl R 1 is hydrogen, hydroxy, lower alkyl, lower alkoxy, R-CO- or R-COO-, wherein R is lower alkyl; R 2 is hydrogen, lower alkyl or cycloalkyl R 3 -R 7 are hydrogen, lower alkyl, lower alkoxy, hydroxy or R 3 and R 4 taken together are -(CH 2 ) n - or R 6 and R 7 taken together are -OCH 2 O- and n is 3 or 4, ```as well as pharmaceutically acceptable salts for the manufacture of medicaments for the control or treatment of diseases which represent therapeutic indications for NMDA receptor subtype specific blockers. Therapeutic indications include acute forms of neurodegeneration e.g. caused by stroke and chronic forms such as Alzheimer's, Parkinson's and Huntingdon's diseases, ALS, schizophrenia, anxiety and depression. Compounds of formala I wherein R 3 and R 4 together form -(CH 2 ) n - are said to be novel. |